Data gathered: November 14
Alternative Data for Cybin
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 89 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Google Trends | 17 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 23 | Sign up | Sign up | Sign up |
| Facebook Followers | 11,742 | Sign up | Sign up | Sign up |
| Instagram Followers | 15,675 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 62 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,715 | Sign up | Sign up | Sign up |
| Twitter Followers | 9,035 | Sign up | Sign up | Sign up |
| Twitter Mentions | 9 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 68 | Sign up | Sign up | Sign up |
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
| Price | $10.80 |
| Target Price | Sign up |
| Volume | 301,470 |
| Market Cap | $237M |
| Year Range | $7.6 - $17.6 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial ResultsNovember 12 - Yahoo |
 |
Cybin Inc: Another High-Risk Psychedelics PlayNovember 2 - SeekingAlpha |
 |
Cybin to Participate at the 2024 Milken Institute Future of Health SummitOctober 30 - Yahoo |
Cybin to Highlight Innovations at Health SummitOctober 30 - TipRanks |
|
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines ProgramOctober 24 - Financial Post |
|
 |
Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines ProgramOctober 24 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 0 | 140,000 | -140,000 | -15M | -20M | -0.020 |
| Q1 '24 | 0 | 140,000 | -140,000 | -21M | -29M | -0.020 |
| Q4 '23 | 0 | 140,000 | -140,000 | -21M | -29M | -0.090 |
| Q3 '23 | 0 | 140,000 | -140,000 | -30M | -27M | -0.050 |
| Q2 '23 | 0 | 69,000 | -69,000 | -12M | -14M | -0.070 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Cybin (CYBN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Cybin?
The Market Cap of Cybin is $237M.
What is the current stock price of Cybin?
Currently, the price of one share of Cybin stock is $10.80.
How can I analyze the CYBN stock price chart for investment decisions?
The CYBN stock price chart above provides a comprehensive visual representation of Cybin's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cybin shares. Our platform offers an up-to-date CYBN stock price chart, along with technical data analysis and alternative data insights.
Does CYBN offer dividends to its shareholders?
As of our latest update, Cybin (CYBN) does not offer dividends to its shareholders. Investors interested in Cybin should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cybin?
Some of the similar stocks of Cybin are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.